This equally randomized (1:1), double-blind, parallel arm study will assess the safety and
antiviral efficacy of RO5024048 added to standard Pegasys (peginterferon alfa-2a) plus
Copegus (ribavirin) therapy in patients with chronic hepatitis C genotype 1 or 4. Patients in
arm A will receive RO5024048 (1000mg orally twice daily) for 24 weeks in addition to Pegasys
(180 micrograms sc weekly) and Copegus (1000mg or 1200mg orally daily). Patients achieving a
rapid virological response (RVR) at week 4, sustained through week 22, will stop all
treatment at week 24; non-RVR patients will continue treatment with Pegasys and Copegus for
another 24 weeks up to week 48. Patients in arm B will receive standard treatment with
Pegasys (180 micrograms sc weekly) and Copegus (1000mg or 1200mg orally daily) for 48 weeks.
Anticipated time on study treatment is up to 48 weeks. Target sample size is <200.